Rainbow Children's growth plan 2026: beds, guidance

What the latest guidance signals

Rainbow Children’s Medical is positioning FY26 as a year of strong growth led by fresh capacity and scaling newer units. Management guided for revenue growth in the range of late-teens to 20% in FY26, with a seasonally soft Q1 expected to be followed by a healthier trend over the next three quarters. The company is also leaning on traction from new verticals such as IVF alongside its core paediatric and women’s healthcare focus. Analysts tracking the stock highlighted a strong ramp-up in new hospitals, with OBD up 20% and ARPOB up 10%.

FY26 revenue outlook and seasonality expectations

Management commentary suggested that Q2 and Q3 typically benefit from seasonality, which flows through to occupancy and revenue. The company indicated mature hospitals run at a “standard regular” occupancy of about 50%, and expects Q2 and Q3 to be around 60% or higher. It also referenced last year’s occupancy at about 65% to 66%, with roughly 10% growth coming from seasonal demand. On that base, management pointed to a typical pattern where occupancy rises by about 8% and revenue grows about 12% in Q2 and Q3. It also indicated revenue generation of about 12% to 14% in that seasonal period.

Expansion cycle status: 780 beds added in two years

Rainbow said it has added close to 780 beds over the past two years through a mix of expansion and acquisitions. Management described this as effectively concluding its current high bed-addition phase. It added that most expansion plans would be completed by FY26, with the next round of expansions expected to come online in FY29.

Commissioned and upcoming hospitals: Rajahmundry and Bengaluru

The company commissioned a new 100-bed hospital in Rajahmundry in Andhra Pradesh. Management noted that with regional hubs in Visakhapatnam, Rajahmundry and Vijayawada, the network would cover many affluent parts of Andhra Pradesh.

In Bengaluru, the 90-bed Electronic City unit was described as fully ready for clinical commencement, but awaiting government approvals. The 60-bed Hennur facility was described as being in the final stages and expected to commence operations by January 2026.

Project timelines and large pipeline into FY27

Rainbow largely retained its bed addition timeline, with some timing shifts. The 100-bed Rajahmundry addition was indicated to be in place by August-end, delayed from Q1 in one reference. Electronic City (90 beds) and Hennur (60 beds) were indicated to be commissioned by end-Q2 in another reference. A Coimbatore hospital of 130 beds is under construction and targeted to commence operations by end-FY27.

Beyond these, the company has two upcoming hospitals in NCR with 450 beds in total, likely to be commissioned in September 2027. A separate data point referenced a 150-bed Pune greenfield regional hub.

Capacity outlook: moving towards 3,015 beds by FY28E

One projection in the provided note expects Rainbow’s total bed capacity to expand to 2,565 by FY27E and further to 3,015 by FY28E. Another estimate stated the company plans to add about 56% new beds over FY25 to FY28E, supporting revenue growth ahead. These estimates are linked to the ramp-up of new hospitals and operating leverage as utilisation improves.

Key operating metrics: occupancy, ALOS, ARPOB and ARPP

Guidance referenced occupancy at 55% in FY27E and 55% to 60% over the next 3 to 5 years as new hospitals mature and capacity ramps up. ALOS is targeted in the range of 2.7 to 2.8 days, indicating a stable case mix and operational efficiency focus.

On pricing and mix, ARPOB growth is expected to be inflation-linked, with management guiding 6% to 7% CAGR, while ARPP is expected to grow at 5% to 6% CAGR. Separately, management also referred to ARPP growing around 5% to 7% CAGR over the long term, while acknowledging quarter-to-quarter volatility.

Financial trajectory: growth and margin guidance

The note includes multiple forward-looking estimates, broadly converging around mid-teen to high-teen growth. One estimate expects revenue and EBITDA CAGR of 15% and 17% over FY25 to FY28E, in line with management’s “high-teen” revenue CAGR commentary. Another estimate referenced a projected 13% revenue CAGR over FY25 to FY28E, while also stating profitability could improve from FY27, with 18% EBITDA CAGR over FY26 to FY28E versus 10% over FY24 to FY26.

On margins, management guided for a base EBITDA margin of 25% (pre Ind AS), with room for improvement as new hospitals mature.

Recent performance datapoint: revenue at INR 450 crore

The note cited a period where revenue grew 12% year-on-year to INR 4.5 billion, supported by healthy ARPOB, though occupancy was lower due to new bed additions. Normalised, INR 4.5 billion equals INR 450 crore. This context is consistent with the company’s current phase where ramp-up and utilisation take time after commissioning.

Summary table: capacity and guidance points

Market impact: what investors tend to track next

For investors, the near-term focus is likely to be the timing of commissioning and approvals for the Bengaluru units, because new beds typically depress occupancy initially before ramp-up. Management commentary also suggests a clear split between mature units growing at 8% to 10% and newer units expected to grow faster, with an aim of about 20% consolidated growth over the next two years. The growth path is being supported by both capacity additions and specialty expansion, with IVF cited as an example of a newer vertical gaining traction.

Why the ramp-up phase matters

The provided note explicitly linked better profitability from FY27 to the ramp-up of new capacity, implying operating leverage once newer hospitals reach breakeven. It also stated that by FY27, most recently commissioned hospitals, including Bengaluru and Chennai units, are expected to reach operating breakeven. In this context, occupancy guidance, ARPOB growth and ALOS targets become key markers for whether the new assets are scaling as planned.

Conclusion

Rainbow Children’s Medical has reiterated a strong growth posture, anchored by late-teen to 20% FY26 revenue guidance and a multi-city bed pipeline that extends into FY27. The immediate operational milestones include government approvals and launches in Bengaluru and continued ramp-up at Rajahmundry, while larger projects such as Coimbatore and the NCR hospitals set the medium-term capacity trajectory.